See other companies on Welcome to the Jungle
SOPHiA GENETICS
Medicine software company
- 501-1000 employees
- Healthcare
- B2B
- Artificial Intelligence
- Analytics
- Machine Learning
- SaaS
- Data Analysis
- MedTech
- Saint-Sulpice, VD
Jump to section
Company mission
To unlock the power of new-generation health data to radically improve outcomes for cancer and rare disease patients around the world today and tomorrow, together.
Our take
Though health and genetic data is increasingly available in large quantities to healthcare providers, it can be very difficult to gain insights from it. Data processing is a significant bottleneck, and important information which could be vital to a patients health can easily be overlooked or misinterpreted. Sophia Genetics has developed a SaaS platform which seeks to change this, by processing raw data received from partner institutions and then returning a standardised report which can be actioned by the end user. The platform then learns from this process, becoming more capable the more data it receives.
The global healthcare AI market is thriving, with numerous large competitors in the sector such as Welltok, iCarbonX and IBM (Watson Health). However, Sophia's USP is its support of democratising health data, which means that it has continually worked closely with a variety of health care providers each using different instruments, providing non-standardised data. While this was initially a hurdle, once overcome it has become a strength, allowing its platform to engage with the equipment a healthcare provider has rather than requiring a particular inventory.
Sophia Genetics went public in 2021 and since then has pursued collaborations with institutions and companies that focus on cancer screening and diagnostics, recently launching a new solution to advance chronic Lymphocytic Leukemia Care in collaboration with IDIBAPS.
Freddie
Company Specialist at Welcome to the Jungle
Company values
- Relentless curiosity
- Resilient and nimble
- Fearlessly adventurous
Funding (last 2 of 6 rounds)
Oct 2020
$110m
SERIES F
Jan 2019
$69.8m
SERIES E
Total funding: $242.8m
This company has top investors
Leadership
Jurgi Camblong
(CEO)Was CEO at Gene Predictis. Prior to that was a Post-doctoral Associate Researcher Oxford University.
Pierre Hutter
(Doctor)REcently founded KLADOS sheltered Foundation. Was CSO at SOPHiA Genetics for 11 years after completing their post-doctoral studies at the University of Edinburgh and the University of Cambridge.
Articles
Jobs (5)
Data
Finance, Legal & Compliance
Other Engineering